The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Nepal Signs 7 MoUs with India for Projects 
• Trump to Hit Patented Drugs with a 100% Tariff 
• Government Looking to Talk with Airlines Amid Fuel Surcharge 
• Bank of Baroda Shares Slip Despite Q4 Global Advances Jumping 16.23%
• Pharma Stocks to be in Focus on Monday as Trump Tariff Reports Rattle Drug Sector

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.